Takeda Oncology Pipeline: Investigational Therapies for Cancer Treatment | Takeda Oncology
Our Pipeline
Our Pipeline
Our oncology R&D activities are focused on translating science into curative or transformative potential treatments through novel strategies that leverage the power of the immune system.
These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.
Investigational therapy | Platform | Investigational indication | Phase | ||
Cabozantinib* | |||||
Targeted therapy | Metastatic castration-resistant prostate cancer (JP) | Phase 3 | |||
Fruquintinib* | |||||
Targeted therapy | Previously treated metastatic colorectal cancer (EU, JP) | Filed | |||
Ponatinib* | |||||
Targeted therapy | Pediatric Ph+ acute lymphoblastic leukemia | Phase 1 | |||
Dazostinag (TAK-676) | |||||
Innate immunity enhancer | Solid tumors | Phase 1/2 | |||
TAK-012 | |||||
Redirected immunity | Acute myeloid leukemia | Phase 1/2a | |||
TAK-186 | |||||
Redirected immunity | Solid tumors | Phase 1/2 | |||
TAK-280 | |||||
Redirected immunity | Solid tumors | Phase 1/2 | |||
TAK-500 | |||||
Innate immunity enhancer | Solid tumors | Phase 1/2 |
*Marketed products have received approval in one or more jurisdictions.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets
Investors
To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page